Dihexa: The Most Potent Nootropic Peptide?
Last updated: March 2026
A hexapeptide derived from angiotensin IV that's claimed to be 10 million times more potent than BDNF at promoting synaptogenesis. Extraordinary claims — but the research base is extraordinarily thin. Here's what we actually know.
🧪 Buy Dihexa at Swiss Chems →(No Clinical Data)
(In Vitro Only)
Harding Lab, WSU
📋 On this page
What Is Dihexa?
Dihexa (PNB-0408) is a synthetic hexapeptide derived from angiotensin IV, developed at Washington State University by Dr. Joseph Harding's laboratory. It activates the hepatocyte growth factor (HGF)/c-Met receptor pathway — a signaling cascade involved in neural development, synaptogenesis, and tissue repair.
Dihexa's primary mechanism: it prevents HGF from being broken down by hepatocyte growth factor activator inhibitor-1 (HAI-1), increasing HGF signaling through the c-Met receptor. This pathway is critical for neural development, synaptic plasticity, and neuronal survival. Unlike BDNF which acts on TrkB receptors, Dihexa works through an entirely different signaling cascade.
In cell culture studies, Dihexa promoted the formation of new synaptic connections at concentrations 10 million times lower than what's required for BDNF to achieve the same effect. This extraordinary potency suggests high receptor binding affinity, but in vitro potency does not directly translate to in vivo cognitive effects due to bioavailability, blood-brain barrier penetration, and metabolic factors.
Angiotensin IV is a naturally occurring peptide fragment that binds to AT4 receptors (now identified as insulin-regulated aminopeptidase/IRAP) in the brain. These receptors are concentrated in memory-associated regions — hippocampus, cortex, and basal forebrain. Dihexa was designed to be a metabolically stable, orally active analog of angiotensin IV with enhanced potency.
HGF/c-Met signaling is heavily implicated in cancer biology. Overactivation of this pathway promotes tumor cell proliferation, invasion, and metastasis. Multiple pharmaceutical companies develop c-Met INHIBITORS as cancer drugs. Dihexa does the opposite — it activates this pathway. The long-term oncological implications of sustained HGF/c-Met activation are unknown and represent a serious theoretical risk.
What the Research Shows
Published data from the Harding lab at Washington State University — the primary (and essentially only) research group studying Dihexa.
Critical context: Nearly all Dihexa research comes from a single lab group at WSU. There are no independent replications, no human clinical trials, and no published safety/toxicology studies. The "10 million times more potent" claim is an in vitro measurement, not a clinical outcome. Treat all data below with extreme caution.
Side Effects & Safety Concerns
With no human trials and limited animal data, the safety profile of Dihexa is essentially unknown.
Drug Interactions & Contraindications
Anyone with a history of cancer or active malignancy should absolutely avoid HGF/c-Met pathway activators. This pathway promotes tumor growth, angiogenesis, and metastasis. This is likely the most significant contraindication.
Combining with other growth factor signaling compounds (BPC-157, GH secretagogues, IGF-1) could amplify proliferative signaling in unpredictable ways. No interaction studies exist.
As an angiotensin IV derivative, theoretical interactions with the renin-angiotensin system exist. Effects on blood pressure regulation when combined with ACE inhibitors or angiotensin receptor blockers are unknown.
With no human pharmacokinetic data, drug interactions are entirely theoretical. CYP450 metabolism, protein binding, and clearance pathways have not been characterized in humans.
Study Citations
The limited published research on Dihexa — nearly all from a single lab group.
Key Takeaways
An honest assessment of where Dihexa research stands — spoiler: it's very early.
- Activates HGF/c-Met pathway for synaptogenesis
- Extraordinary in vitro potency (10M× BDNF)
- Improved cognition in scopolamine-impaired rats
- Restored aged rat memory to young levels
- Designed as metabolically stable angiotensin IV analog
- Orally bioactive in animal models
- Zero human clinical trial data
- No independent replication of findings
- Long-term cancer risk from c-Met activation
- Human pharmacokinetics — oral bioavailability unknown
- Effective dose in humans vs anecdotal reports
- Drug interactions and contraindications
- Whether in vitro potency translates to cognitive benefit
🛒 Recommended Products
Support supplements and tools for nootropic research — since Dihexa itself is an experimental research chemical.
Affiliate links help support HighPeptides at no extra cost to you.
Related Resources
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. It is not medical advice. Dihexa (PNB-0408) is not approved by the FDA or any regulatory body for human use. It is an experimental research chemical with no published human safety data. The HGF/c-Met pathway it activates is implicated in cancer biology. All research comes from a single lab group with no independent replication. Self-experimentation with Dihexa carries significant unknown risks. Always consult a qualified healthcare provider before using any experimental compound. Not Approved Research Chemical